Close Menu

NEW YORK – T2 Biosystems turned in subpar fourth quarter and full year revenues, missing estimates despite its unique advantages and head starts in the rapid molecular diagnostics space. With a CEO transition completed six weeks ago, however, the firm has now announced plans to cut costs and focus on targeting sales of its sepsis tests in new ways to improve margins.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.